Ivabradine Mercury Pharmaceuticals

Ivabradine, the active ingredient in Ivabradine Mercury Pharmaceuticals, is an If channel inhibitor presented as an oral tablet for systemic use. It is indicated for the management of chronic stable angina and for symptomatic relief in patients with heart failure, primarily in adult populations.

GNH USA supplies Ivabradine Mercury Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring product integrity throughout the supply chain.

Ivabradine acts on the cardiac If channel to control heart rate in ischemic and heart‑failure conditions.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure: improves symptoms and may lower hospitalization risk by decreasing myocardial oxygen demand.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - High‑grade atrioventricular block. - Persistent visual loss. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate cardiac status and concomitant medications.

- Cardiac monitoring: assess baseline heart rate and rhythm. - Avoid in severe hypotension: do not start if systolic BP <90 mmHg. - Caution with sick sinus syndrome: may exacerbate bradyarrhythmias. - Do not combine with strong CYP3A4 inhibitors without dose adjustment. - Pregnancy and lactation: use only if potential benefit justifies risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ivabradine may interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Co‑administration with other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - QT‑prolonging drugs (e.g., amiodarone): heightened risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may modestly raise ivabradine concentrations. - Other antiarrhythmics (e.g., flecainide): monitor heart rhythm. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.